Login to Your Account



Merck files BLA for anti-PD-1 immunotherapy

By Michael Fitzhugh
Staff Writer

Tuesday, May 6, 2014
regulatory.jpg

Merck & Co. Inc. on Tuesday completed filing its FDA biologics license application for MK-3475 (pembrolizumab), its high-profile programmed cell death 1 (PD-1) inhibitor. The company is seeking approval to treat melanoma patients unsuccessfully treated with Yervoy (ipilimumab, Bristol-Myers Squibb Co.), an indication for which the FDA has granted it both breakthrough designation and priority review status.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription